scholarly journals Impact of synthetic surfactant CHF5633 with SP‐B and SP‐C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Pavol Mikolka ◽  
Tore Curstedt ◽  
Riccardo Feinstein ◽  
Anders Larsson ◽  
Marian Grendar ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Lung Function ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Rabbit Model ◽  
Synthetic Surfactant

scholarly journals Monitoring of lung function in acute respiratory distress syndrome

2017 ◽  
Vol 5 (14) ◽  
pp. 284-284 ◽  
Author(s):  
Anders Larsson ◽  
Claude Guerin
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Lung Function ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome

scholarly journals Synthetic surfactant with a recombinant surfactant protein C analogue improves lung function and attenuates inflammation in a model of acute respiratory distress syndrome in adult rabbits

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
J. Zebialowicz Ahlström ◽  
F. Massaro ◽  
P. Mikolka ◽  
R. Feinstein ◽  
G. Perchiazzi ◽  
...  
Keyword(s):  
Body Weight ◽  
Acute Respiratory Distress Syndrome ◽  
Lung Function ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Protein C ◽  
Distress Syndrome ◽  
Surfactant Protein ◽  
Lung Oedema ◽  
Surfactant Protein C

Abstract Aim In acute respiratory distress syndrome (ARDS) damaged alveolar epithelium, leakage of plasma proteins into the alveolar space and inactivation of pulmonary surfactant lead to respiratory dysfunction. Lung function could potentially be restored with exogenous surfactant therapy, but clinical trials have so far been disappointing. These negative results may be explained by inactivation and/or too low doses of the administered surfactant. Surfactant based on a recombinant surfactant protein C analogue (rSP-C33Leu) is easy to produce and in this study we compared its effects on lung function and inflammation with a commercial surfactant preparation in an adult rabbit model of ARDS. Methods ARDS was induced in adult New Zealand rabbits by mild lung-lavages followed by injurious ventilation (VT 20 m/kg body weight) until P/F ratio < 26.7 kPa. The animals were treated with two intratracheal boluses of 2.5 mL/kg of 2% rSP-C33Leu in DPPC/egg PC/POPG, 50:40:10 or poractant alfa (Curosurf®), both surfactants containing 80 mg phospholipids/mL, or air as control. The animals were subsequently ventilated (VT 8–9 m/kg body weight) for an additional 3 h and lung function parameters were recorded. Histological appearance of the lungs, degree of lung oedema and levels of the cytokines TNFα IL-6 and IL-8 in lung homogenates were evaluated. Results Both surfactant preparations improved lung function vs. the control group and also reduced inflammation scores, production of pro-inflammatory cytokines, and formation of lung oedema to similar degrees. Poractant alfa improved compliance at 1 h, P/F ratio and PaO2 at 1.5 h compared to rSP-C33Leu surfactant. Conclusion This study indicates that treatment of experimental ARDS with synthetic lung surfactant based on rSP-C33Leu improves lung function and attenuates inflammation.

scholarly journals Effects of Early Continuous Venovenous Hemofiltration on E-Selectin, Hemodynamic Stability, and Ventilatory Function in Patients with Septic-Shock-Induced Acute Respiratory Distress Syndrome

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Jian-biao Meng ◽  
Zhi-zhen Lai ◽  
Xiu-juan Xu ◽  
Chun-lian Ji ◽  
Ma-hong Hu ◽  
...  
Keyword(s):  
Septic Shock ◽  
Mechanical Ventilation ◽  
Acute Respiratory Distress Syndrome ◽  
Lung Function ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Randomized Study ◽  
Continuous Venovenous Hemofiltration ◽  
Hemodynamic Stability

Objective. To investigate the effects of 72-hour early-initiated continuous venovenous hemofiltration (ECVVH) treatment in patients with septic-shock-induced acute respiratory distress syndrome (ARDS) (not acute kidney injury, AKI) with regard to serum E-selectin and measurements of lung function and hemodynamic stability.Methods. This prospective nonblinded single institutional randomized study involved 51 patients who were randomly assigned to receive or not receive ECVVH, an ECVVH group (n=24) and a non-ECVVH group (n=27). Besides standard therapies, patients in ECVVH group underwent CVVH for 72 h.Results. At 0 and 24 h after initiation of treatment, arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio, extravascular lung water index (EVLWI), and E-selectin level were not significantly different between groups (allP>0.05). Compared to non-ECVVH group, PaO2/FiO2is significantly higher and EVLWI and E-selectin level are significantly lower in ECVVH group (allP<0.05) at 48 h and 72 h after initiation of treatment. The lengths of mechanical ventilation and stay in intensive care unit (ICU) were shorter in ECVVH group (allP<0.05), but there was no difference in 28-day mortality between two groups.Conclusions. In patients with septic-shock-induced ARDS (not AKI), treatment with ECVVH in addition to standard therapies improves endothelial function, lung function, and hemodynamic stability and reduces the lengths of mechanical ventilation and stay in ICU.

scholarly journals Two Hours of In Vivo Lung Perfusion Improves Lung Function in Sepsis-Induced Acute Respiratory Distress Syndrome

2021 ◽  
Author(s):  
Matthew R. Byler ◽  
Nathan S. Haywood ◽  
Dustin T. Money ◽  
Aimee Zhang ◽  
Jared P. Beller ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Lung Function ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Lung Perfusion
Sign in / Sign up

Export Citation Format

Share Document